Restoration of p53 Functions By Suppression of mortalin–p53 Sequestration: an Emerging Target in Cancer Therapy

References

• WHO . Cancer (2022). www.who.int/news-room/fact-sheets/detail/cancer
   Google Scholar
• Ando K , OkiE, ZhaoYet al. Mortalin is a prognostic factor of gastric cancer with normal p53 function. Gastric Cancer17(2), 255–262 (2014).
   PubMed Web of Science ®Google Scholar
• Niazi S , PurohitM, NiaziJH. Role of p53 circuitry in tumorigenesis: a brief review. Eur. J. Med. Chem.158, 7–24 (2018).
   PubMed Web of Science ®Google Scholar
• Lu WJ , LeeNP, KaulSCet al. Mortalin–p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Diff.18(6), 1046–1056 (2011).
   PubMed Web of Science ®Google Scholar
• Moseng MA , NixJC, PageRC. 2- and N6-functionalized adenosine-5′-diphosphate analogs for the inhibition of mortalin. FEBS Lett.593(15), 2030–2039 (2019).
   PubMed Web of Science ®Google Scholar
• Furet P , MasuyaK, KallenJet al. Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument. Bioorg. Med. Chem. Lett.26(19), 4837–4841 (2016).
   PubMed Web of Science ®Google Scholar
• Wadhwa R , TakanoS, KaurKet al. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int. J. Cancer118(12), 2973–2980 (2006).
   PubMed Web of Science ®Google Scholar
• Tai-Nagara I , MatsuokaS, ArigaH, SudaT. Mortalin and DJ-1 coordinately regulate hematopoietic stem cell function through the control of oxidative stress. Blood123(1), 41–50 (2014).
   PubMed Web of Science ®Google Scholar
• Kanai M , MaZ, IzumiHet al. Physical and functional interaction between mortalin and Mps1 kinase. Genes Cells12(6), 797–810 (2007).
   PubMed Web of Science ®Google Scholar
• Wadhwa R , YaguchiT, HasanMK, TairaK, KaulSC. Mortalin–MPD (mevalonate pyrophosphate decarboxylase) interactions and their role in control of cellular proliferation. Biochem. Biophys. Res. Commun.302(4), 735–742 (2003).
   PubMed Web of Science ®Google Scholar
• Chen J , LiuWB, JiaWDet al. Overexpression of mortalin in hepatocellular carcinoma and its relationship with angiogenesis and epithelial to mesenchymal transition. Int. J. Oncol.44(1), 247–255 (2014).
   PubMed Web of Science ®Google Scholar
• Ryu J , KaulZ, YoonARet al. Identification and functional characterization of nuclear mortalin in human carcinogenesis. J. Biol. Chem.289(36), 24832–24844 (2014).
   PubMed Web of Science ®Google Scholar
• Daniele S , SestitoS, PietrobonoDet al. Dual inhibition of PDK1 and aurora kinase a: an effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells. ACS Chem. Neurosci.8(1), 100–114 (2017).
   PubMed Web of Science ®Google Scholar
• Yang L , GuoW, ZhangQet al. Crosstalk between Raf/MEK/ERK and PI3K/AKT in suppression of Bax conformational change by Grp75 under glucose deprivation conditions. J. Mol. Biol.414(5), 654–666 (2011).
   PubMed Web of Science ®Google Scholar
• Cui X , LiZ, PiaoJet al. Mortalin expression in pancreatic cancer and its clinical and prognostic significance. Hum. Pathol.64, 171–178 (2017).
   PubMed Web of Science ®Google Scholar
• Na Y , KaulSC, RyuJet al. Stress chaperone mortalin contributes to epithelial-to-mesenchymal transition and cancer metastasis. Cancer Res.76(9), 2754–2765 (2016).
   PubMed Web of Science ®Google Scholar
• Kussie PH , GorinaS, MarechalVet al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science274(5289), 948–953 (1996).
   PubMed Web of Science ®Google Scholar
• Popowicz GM , CzarnaA, HolakTA. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle7(15), 2441–2443 (2008).
   PubMed Web of Science ®Google Scholar
• Bochkareva E , KaustovL, AyedAet al. Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc. Natl Acad. Sci. USA102(43), 15412–15417 (2005).
   PubMed Web of Science ®Google Scholar
• Baptiste N , FriedlanderP, ChenX, PrivesC. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene21(1), 9–21 (2002).
   PubMed Web of Science ®Google Scholar
• Wang Y , RosengarthA, LueckeH. Structure of the human p53 core domain in the absence of DNA. Acta Crystallogr. Sect. D63(3), 276–281 (2007).
   PubMedGoogle Scholar
• Cho Y , GorinaS, JeffreyPD, PavletichNP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science265(5170), 346–355 (1994).
   PubMed Web of Science ®Google Scholar
• Pérez Cañadillas JM , TidowH, FreundSMV, RutherfordTJ, AngHC, FershtAR. Solution structure of p53 core domain: structural basis for its instability. Proc. Natl Acad. Sci. USA103(7), 2109–2114 (2006).
   PubMed Web of Science ®Google Scholar
• Ho WC , FitzgeraldMX, MarmorsteinR. Structure of the p53 core domain dimer bound to DNA. J. Biol. Chem.281(29), 20494–20502 (2006).
   PubMed Web of Science ®Google Scholar
• Kitayner M , RozenbergH, KesslerNet al. Structural basis of DNA recognition by p53 tetramers. Mol. Cell22(6), 741–753 (2006).
   PubMed Web of Science ®Google Scholar
• Joerger AC , FershtAR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb. Perspect. Biol.2(6), doi: 10.1101/cshperspect.a000919 (2010).
   PubMed Web of Science ®Google Scholar
• Stommel JM , MarchenkoND, JimenezGS, MollUM, HopeTJ, WahlGM. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J.18(6), 1660–1672 (1999).
   PubMed Web of Science ®Google Scholar
• Tidow H , MeleroR, MylonasEet al. Quaternary structures of tumor suppressor p53 and a specific p53-DNA complex. Proc. Natl Acad. Sci. USA104(30), 12324–12329 (2007).
   PubMed Web of Science ®Google Scholar
• Wells M , TidowH, RutherfordTJet al. Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Proc. Natl Acad. Sci. USA105(15), 5762–5767 (2008).
   PubMed Web of Science ®Google Scholar
• Ramraj SK , ElayapillaiSP, PelikanRCet al. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. Int. J. Cancer147(4), 1086–1097 (2020).
   PubMed Web of Science ®Google Scholar
• Zhu G , PanC, BeiJXet al. Mutant p53 in cancer progression and targeted therapies. Front. Oncol.10(November), 1–9 (2020).
   PubMedGoogle Scholar
• Boutelle AM , AttardiLD. p53 and tumor suppression: it takes a network. Trends Cell Biol.31(4), 298–310 (2021).
   PubMed Web of Science ®Google Scholar
• Aubrey BJ , KellyGL, JanicA, HeroldMJ, StrasserA. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?Cell Death Diff.25(1), 104–113 (2017).
   PubMed Web of Science ®Google Scholar
• Kruiswijk F , LabuschagneCF, VousdenKH. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat. Rev. Mol. Cell Biol.16(7), 393–405 (2015).
   PubMed Web of Science ®Google Scholar
• Lacroix M , RiscalR, ArenaG, LinaresLK, LeCam L. Metabolic functions of the tumor suppressor p53: implications in normal physiology, metabolic disorders, and cancer. Mol. Metab.33, 2–22 (2020).
   PubMed Web of Science ®Google Scholar
• Moon SH , HuangCH, HoulihanSLet al. p53 represses the mevalonate pathway to mediate tumor suppression. Cell176(3), 564–580 (2019).
   PubMed Web of Science ®Google Scholar
• Jiang L , KonN, LiTet al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature520(7545), 57–62 (2015).
   PubMed Web of Science ®Google Scholar
• Ou Y , WangSJ, LiD, ChuB, GuW. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc. Natl Acad. Sci. USA113(44), E6806–E6812 (2016).
   PubMed Web of Science ®Google Scholar
• Kim NH , KimHS, LiXYet al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition. J. Cell Biol.195(3), 417–433 (2011).
   PubMed Web of Science ®Google Scholar
• Wang SP , WangWL, ChangYLet al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat. Cell Biol.11(6), 694–704 (2009).
   PubMed Web of Science ®Google Scholar
• Chang CJ , ChaoCH, XiaWet al. p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol.13(3), 317–323 (2011).
   PubMed Web of Science ®Google Scholar
• Assadian S , El-AssaadW, WangXQDet al. p53 inhibits angiogenesis by inducing the production of arresten. Cancer Res.72(5), 1270–1279 (2012).
   PubMed Web of Science ®Google Scholar
• Teodoro JG , EvansSK, GreenMR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J. Mol. Med.85(11), 1175–1186 (2007).
   PubMed Web of Science ®Google Scholar
• Ho T , TanBX, LaneD. How the other half lives: what p53 does when it is not being a transcription factor. Int. J. Mol. Sci.21(1), 1–19 (2019).
   PubMed Web of Science ®Google Scholar
• Kadosh E , Snir-AlkalayI, VenkatachalamAet al. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature586(7827), 133–138 (2020).
   PubMed Web of Science ®Google Scholar
• Pan M , BlattnerC. Regulation of p53 by E3s. Cancers (Basel)13(4), 745 (2021).
   PubMed Web of Science ®Google Scholar
• Vijayakumaran R , TanKH, MirandaPJ, HauptS, HauptY. Regulation of mutant p53 protein expression. Front. Oncol.5(Dec), 3–10 (2015).
   PubMedGoogle Scholar
• Boehme KA , KulikovR, BlattnerC. p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc. Natl Acad. Sci. USA105(22), 7785–7790 (2008).
   PubMed Web of Science ®Google Scholar
• Carr MI , JonesSN. Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis. Transl. Cancer Res.5(6), 707–724 (2016).
   PubMed Web of Science ®Google Scholar
• Zindy F , EischenCM, RandleDHet al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev.12(15), 2424–2433 (1998).
   PubMed Web of Science ®Google Scholar
• Zhou X , CaoB, LuH. Negative auto-regulators trap p53 in their web. J. Mol. Cell Biol.9(1), 62–68 (2017).
   PubMed Web of Science ®Google Scholar
• Yu H , YueX, ZhaoYet al. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat. Commun.5(1), 1–12 (2014).
   Google Scholar
• Krzeszinski JY , ChoeV, ShaoJet al. XPC promotes MDM2-mediated degradation of the p53 tumor suppressor. Mol. Biol. Cell25(2), 213–221 (2014).
   PubMed Web of Science ®Google Scholar
• Latini P , FrontiniM, CaputoMet al. CSA and CSB proteins interact with p53 and regulate its Mdm2-dependent ubiquitination. Cell Cycle10(21), 3719–3730 (2011).
   PubMed Web of Science ®Google Scholar
• Leng RP , LinY, MaWet al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell112(6), 779–791 (2003).
   PubMed Web of Science ®Google Scholar
• Dornan D , WertzI, ShimizuHet al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature429(6987), 86–92 (2004).
   PubMed Web of Science ®Google Scholar
• Liu J , ZhangC, WangXLet al. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Diff.21(11), 1792–1804 (2014).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cano L , HilljeAL, Fuertes-AlvarezSet al. Regulatory feedback loop between TP73 and TRIM32. Cell Death Dis.4(7), e704 (2013).
   PubMedGoogle Scholar
• Lu X , MaO, NguyenTA, JonesSN, OrenM, DonehowerLA. The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell12(4), 342–354 (2007).
   PubMed Web of Science ®Google Scholar
• Yan J , JiangJ, ChingAL, WuQ, NgHH, ChinKC. BLIMP1 regulates cell growth through repression of p53 transcription. Proc. Natl Acad. Sci. USA104(6), 1841–1846 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang J , ChoSJ, ShuLet al. Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas. Genes Dev.25(14), 1528–1543 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang J , SuB, GongC, XiQ, ChaoT. miR-214 promotes apoptosis and sensitizes breast cancer cells to doxorubicin by targeting the RFWD2-p53 cascade. Biochem. Biophys. Res. Commun.478(1), 337–342 (2016).
   PubMed Web of Science ®Google Scholar
• Zhou X , HaoQ, LiaoPet al. Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator. Elife5(Jun), 1–22 (2016).
   Google Scholar
• Elwakeel A . Abrogating the interaction between p53 and mortalin (Grp75/HSPA9/mtHsp70) for cancer therapy: the story so far. Front. Cell Dev. Biol.10, 697 (2022).
   Web of Science ®Google Scholar
• Amick J , SchlangerSE, WachnowskyCet al. Crystal structure of the nucleotide-binding domain of mortalin, the mitochondrial Hsp70 chaperone. Protein Sci.23(6), 833–842 (2014).
   PubMed Web of Science ®Google Scholar
• Radons J . The human HSP70 family of chaperones: where do we stand?Cell Stress Chaperones21(3), 379–404 (2016).
   PubMed Web of Science ®Google Scholar
• Ferré CA , ThouardA, BétournéAet al. HSPA9/mortalin mediates axo-protection and modulates mitochondrial dynamics in neurons. Sci. Rep.11(1), 1–12 (2021).
   PubMed Web of Science ®Google Scholar
• Esfahanian N , KnoblichCD, BowmanGA, RezvaniK. Mortalin: protein partners, biological impacts, pathological roles, and therapeutic opportunities. Front. Cell Dev. Biol.11(February), 1–11 (2023).
   Google Scholar
• Texier B , PrimeM, AtamenaD, BelenguerP, SzelechowskiM. Mortalin/Hspa9 involvement and therapeutic perspective in Parkinson's disease. Neural Regen. Res.18(2), 293–298 (2023).
   PubMed Web of Science ®Google Scholar
• Flachbartová Z , KovacechB. Mortalin–a multipotent chaperone regulating cellular processes ranging from viral infection to neurodegeneration. Acta Virol.57(1), 3–15 (2013).
   PubMed Web of Science ®Google Scholar
• D'Silva P , LiuQ, WalterW, CraigEA. Regulated interactions of mtHsp70 with Tim44 at the translocon in the mitochondrial inner membrane. Nat. Struct. Mol. Biol.11(11), 1084–1091 (2004).
   PubMed Web of Science ®Google Scholar
• Kleczewska M , GrabinskaA, JelenMet al. Biochemical convergence of mitochondrial Hsp70 system specialized in iron–sulfur cluster biogenesis. Int. J. Mol. Sci.21(9), 3326 (2020).
   PubMed Web of Science ®Google Scholar
• Pilzer D , FishelsonZ. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis. Int. Immunol.17(9), 1239–1248 (2005).
   PubMed Web of Science ®Google Scholar
• Shih YY , LeeH, NakagawaraAet al. Nuclear GRP75 binds retinoic acid receptors to promote neuronal differentiation of neuroblastoma. PLOS ONE6(10), e26236 (2011).
   PubMed Web of Science ®Google Scholar
• Londono C , OsorioC, GamaV, AlzateO. Mortalin, apoptosis, and neurodegeneration. Biomolecules2(1), 143–164 (2012).
   PubMedGoogle Scholar
• Sane S , HafnerA, SrinivasanRet al. UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells. Mol. Oncol.12(10), 1753–1777 (2018).
   PubMed Web of Science ®Google Scholar
• Feng S , HuangQ, DengJet al. DAB2IP suppresses tumor malignancy by inhibiting GRP75-driven p53 ubiquitination in colon cancer. Cancer Lett.532, doi: 10.1016/j.canlet.2022.215588 (2022).
   PubMed Web of Science ®Google Scholar
• Chen X , XuB, LiHet al. Expression of mortalin detected in human liver cancer by tissue microarrays. Anat. Rec. Adv. Integr. Anat. Evol. Biol.294(8), 1344–1351 (2011).
   Web of Science ®Google Scholar
• Takano S , WadhwaR, YoshiiY, NoseT, KaulSC, MitsuiY. Elevated levels of mortalin expression in human brain tumors. Exp. Cell Res.237(1), 38–45 (1997).
   PubMed Web of Science ®Google Scholar
• Rozenberg P , KocsisJ, SaarM, ProhászkaZ, FüstG, FishelsonZ. Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer. Int. J. Cancer133(2), 514–518 (2013).
   PubMed Web of Science ®Google Scholar
• Starenki D , SosonkinaN, HongSK, LloydRV, ParkJI. Mortalin (GRP75/HSPA9) promotes survival and proliferation of thyroid carcinoma cells. Int. J. Mol. Sci.20(9), 2069 (2019).
   PubMed Web of Science ®Google Scholar
• Xu M , JinT, ChenLet al. Mortalin is a distinct bio-marker and prognostic factor in serous ovarian carcinoma. Gene696, 63–71 (2019).
   PubMed Web of Science ®Google Scholar
• Jin H , JiM, ChenLet al. The clinicopathological significance of mortalin overexpression in invasive ductal carcinoma of breast. J. Exp. Clin. Cancer Res.35(1), 1–9 (2016).
   PubMedGoogle Scholar
• Sun J , CheSL, PiaoJJ, XuM, ChenLY, LinZH. Mortalin overexpression predicts poor prognosis in early stage of non–small cell lung cancer. Tumor Biol.39(3), 1–9 (2017).
   Google Scholar
• Pui-Kei W , Seung-KeunH, SudhakarVet al. A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase. Mol. Cell. Biol.33(20), 4051–4067 (2013).
   PubMed Web of Science ®Google Scholar
• Ma Z , IzumiH, KanaiM, KabuyamaY, AhnNG, FukasawaK. Mortalin controls centrosome duplication via modulating centrosomal localization of p53. Oncogene25(39), 5377–5390 (2006).
   PubMed Web of Science ®Google Scholar
• Yi X , LukJM, LeeNPet al. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol. Cell. Proteomics7(2), 315–325 (2008).
   PubMed Web of Science ®Google Scholar
• Sane S , AbdullahA, BoudreauDAet al. Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-mortalin interactions in colon cancer cells. Cell Death Dis.5(3), e1118 (2014).
   PubMedGoogle Scholar
• Wadhwa R , TakanoS, RobertMet al. Inactivation of tumor suppressor p53 by Mot-2, a hsp70 family member. J. Biol. Chem.273(45), 29586–29591 (1998).
   PubMed Web of Science ®Google Scholar
• Kaul SC , TakanoS, ReddelRR, MitsuiY, WadhwaR. Transcriptional Inactivation of p53 by deletions and single amino acid changes in mouse mot-1 protein. Biochem. Biophys. Res. Commun.279(2), 602–606 (2000).
   PubMed Web of Science ®Google Scholar
• Kaul SC , AidaS, YaguchiT, KaurK, WadhwaR. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J. Biol. Chem.280(47), 39373–39379 (2005).
   PubMed Web of Science ®Google Scholar
• Gestl EE , AnneBöttger S. Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines. Biochem. Biophys. Res. Commun.423(2), 411–416 (2012).
   PubMed Web of Science ®Google Scholar
• Kaul SC , ReddelRR, MitsuiY, WadhwaR. An N-terminal region of Mot-2 binds to p53 in vitro. Neoplasia3(2), 110–114 (2001).
   PubMed Web of Science ®Google Scholar
• Kaul SC , TakanoS, ReddelRR, MitsuiY, WadhwaR. Transcriptional inactivation of p53 by deletions and single amino acid changes in mouse mot-1 protein. Biochem. Biophys. Res. Commun.279(2), 602–606 (2000).
   PubMed Web of Science ®Google Scholar
• Iosefson O , AzemA. Reconstitution of the mitochondrial Hsp70 (mortalin)-p53 interaction using purified proteins–identification of additional interacting regions. FEBS Lett.584(6), 1080–1084 (2010).
   PubMed Web of Science ®Google Scholar
• Moll UM , WolffS, SpeidelD, DeppertW. Transcription-independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol.17(6), 631–636 (2005).
   PubMed Web of Science ®Google Scholar
• Ramraj SK , ElayapillaiSP, PelikanRCet al. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. Int. J. Cancer147(4), 1086–1097 (2020).
   PubMed Web of Science ®Google Scholar
• Yang L , LiuX, HaoJet al. Glucose-regulated protein 75 suppresses apoptosis induced by glucose deprivation in PC12 cells through inhibition of Bax conformational change. Acta Biochim. Biophys. Sin.40(4), 339–348 (2008).
   Google Scholar
• Wei B , CaoJ, TianJ-Het al. Mortalin maintains breast cancer stem cells stemness via activation of Wnt/GSK3β/β-catenin signaling pathway. Am. J. Cancer Res.11(6), 2696 (2021).
   PubMed Web of Science ®Google Scholar
• Propper DJ , BraybrookeJP, TaylorDJet al. Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours. Ann. Oncol.10(8), 923–927 (1999).
   PubMed Web of Science ®Google Scholar
• Wadhwa R , SugiharaT, YoshidaAet al. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res.60(24), 6818–6821 (2000).
   PubMed Web of Science ®Google Scholar
• Hong SK , StarenkiD, JohnsonOT, GestwickiJE, ParkJI. Analogs of the heat shock protein 70 inhibitor MKT-077 suppress medullary thyroid carcinoma cells. Int. J. Mol. Sci.23(3), 1063 (2022).
   PubMed Web of Science ®Google Scholar
• Li YX , ZhaiX, LiaoWK, ZhuWF, HeY, GongP. Design, synthesis and biological evaluation of new rhodacyanine analogues as potential antitumor agents. Chin. Chem. Lett.23(4), 415–418 (2012).
   Web of Science ®Google Scholar
• Putri JF , BhargavaP, DhanjalJKet al. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers. J. Exp. Clin. Cancer Res.38(1), 1–15 (2019).
   PubMed Web of Science ®Google Scholar
• Sari AN , ElwakeelA, DhanjalJKet al. Identification and characterization of MortaparibPlus–a novel triazole derivative that targets mortalin-p53 interaction and inhibits cancer-cell proliferation by wild-type p53-dependent and -independent mechanisms. Cancers (Basel)13(4), 835 (2021).
   PubMed Web of Science ®Google Scholar
• Meidinna HN , ShefrinS, SariANet al. Identification of a new member of mortaparib class of inhibitors that target mortalin and PARP1. Front. Cell Dev. Biol.10, doi: 10.3389/fcell.2022.918970 (2022).
   PubMed Web of Science ®Google Scholar
• Benbrook DM , NammalwarB, LongAet al. SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres. Invest. New Drugs32(3), 412–423 (2014).
   PubMed Web of Science ®Google Scholar
• Benbrook DM . SHetA2 attack on mortalin and colleagues in cancer therapy and prevention. Front. Cell Dev. Biol.10(February), 1–13 (2022).
   Google Scholar
• Chandra V , RaiR, BenbrookDM. Utility and mechanism of sheta2 and paclitaxel for treatment of endometrial cancer. Cancers (Basel)13(10), 1–19 (2021).
   Web of Science ®Google Scholar
• Park SH , BaekKH, ShinI, ShinI. Subcellular Hsp70 inhibitors promote cancer cell death via different mechanisms. Cell Chem. Biol.25(10), 1242–1254 (2018).
   PubMed Web of Science ®Google Scholar
• Grover A , PriyandokoD, GaoRet al. Withanone binds to mortalin and abrogates mortalin–p53 complex: computational and experimental evidence. Int. J. Biochem. Cell Biol.44(3), 496–504 (2012).
   PubMed Web of Science ®Google Scholar
• Wadhwa R , NigamN, BhargavaPet al. Molecular characterization and enhancement of anticancer activity of caffeic acid phenethyl ester by γ cyclodextrin. J. Cancer7(13), 1755–1771 (2016).
   PubMed Web of Science ®Google Scholar
• Bhargava P , GroverA, NigamNet al. Anticancer activity of the supercritical extract of Brazilian green propolis and its active component, artepillin C: bioinformatics and experimental analyses of its mechanisms of action. Int. J. Oncol.52(3), 925–932 (2018).
   PubMed Web of Science ®Google Scholar
• Garg S , AfzalS, ElwakeelAet al. Marine carotenoid fucoxanthin possesses anti-metastasis activity: molecular evidence. Mar. Drugs17(6), 338 (2019).
   PubMed Web of Science ®Google Scholar
• Nigam N , GroverA, GoyalSet al. Targeting mortalin by embelin causes activation of tumor suppressor p53 and deactivation of metastatic signaling in human breast cancer cells. PLOS ONE10(9), e0138192 (2015).
   PubMed Web of Science ®Google Scholar
• Kurnia Hartati F , BesariDjauhari A. Potential of black rice (Oryza sativa L.) as anticancer through mortalin-p53 complex inhibitors. Biointerface Res. Appl. Chem.10(5), 6174–6181 (2020).
   Web of Science ®Google Scholar
• Nagpal N , GoyalS, DhanjalJKet al. Molecular dynamics-based identification of novel natural mortalin–p53 abrogators as anticancer agents. J. Recept. Signal Transduct.37(1), 8–16 (2016).
   PubMed Web of Science ®Google Scholar
• Abdullah A , SaneS, BranickKAet al. A plant alkaloid, veratridine, potentiates cancer chemosensitivity by UBXN2A-dependent inhibition of an oncoprotein, mortalin-2. Oncotarget6(27), 23561–23581 (2015).
   PubMedGoogle Scholar
• Utomo DH , WidodoN, Rifa'iM. Identifications small molecules inhibitor of p53-mortalin complex for cancer drug using virtual screening. Bioinformation8(9), 429 (2012).
   Google Scholar
• Sari AN , BhargavaP, DhanjalJKet al. Combination of withaferin-A and CAPE provides superior anticancer potency: bioinformatics and experimental evidence to their molecular targets and mechanism of action. Cancers (Basel)12(5), 1160 (2020).
   PubMed Web of Science ®Google Scholar
• Pham MQ , TranTHV, PhamQL, GairinJE. In silico analysis of the binding properties of solasonine to mortalin and p53, and in vitro pharmacological studies of its apoptotic and cytotoxic effects on human HepG2 and Hep3b hepatocellular carcinoma cells. Fundam. Clin. Pharmacol.33(4), 385–396 (2019).
   PubMed Web of Science ®Google Scholar
• Buchwald P . Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. IUBMB Life62(10), 724–731 (2010).
   PubMed Web of Science ®Google Scholar
• Cui W , AouidateA, WangS, YuQ, LiY, YuanS. Discovering anti-cancer drugs via computational methods. Front. Pharmacol.11, 733 (2020).
   PubMed Web of Science ®Google Scholar
• Macalino SJY , BasithS, ClavioNAB, ChangH, KangS, ChoiS. Evolution of in silico strategies for protein-protein interaction drug discovery. Molecules23(8), 1963 (2018).
   PubMed Web of Science ®Google Scholar
• Wang L , WangN, ZhangWet al. Therapeutic peptides: current applications and future directions. Signal Transduct. Target. Ther.7(1), 1–27 (2022).
   PubMed Web of Science ®Google Scholar
• Kaul SC , AidaS, YaguchiT, KaurK, WadhwaR. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J. Biol. Chem.280(47), 39373–39379 (2005).
   PubMed Web of Science ®Google Scholar
• Bulcha JT , WangY, MaH, TaiPWL, GaoG. Viral vector platforms within the gene therapy landscape. Signal Transduct. Target. Ther.6(1), 1–24 (2021).
   PubMed Web of Science ®Google Scholar
• Yoo JY , RyuJ, GaoRet al. Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus. J. Gene Med.12(7), 586–595 (2010).
   PubMed Web of Science ®Google Scholar
• Yu AM , ChoiYH, TuMJ. RNA drugs and RNA targets for small molecules: principles, progress, and challenges. Pharmacol. Rev.72(4), 862–898 (2020).
   PubMed Web of Science ®Google Scholar
• Sari S , TomekP, LeungE, ReynissonJ. Discovery and characterisation of dual inhibitors of tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase 1 (IDO1) using virtual screening. Molecules24(23), 1–19 (2019).
   Web of Science ®Google Scholar
• Zhao L , ZhaoJ, ZhongK, TongA, JiaD. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct. Target. Ther.7(1), 1–13 (2022).
   PubMed Web of Science ®Google Scholar